(Q46356731)

English

Cysteine proteinase type III is protective against Leishmania infantum infection in BALB/c mice and highly antigenic in visceral leishmaniasis individuals

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18804512

Cysteine proteinase type III is protective against Leishmania infantum infection in BALB/c mice and highly antigenic in visceral leishmaniasis individuals (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18804512

visceral leishmaniasis

1 reference

based on heuristic

inferred from title

Leishmania infantum

1 reference

based on heuristic

inferred from title

6

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18804512

author name string

Naghmeh Khoshgoo

1

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18804512

Farnaz Zahedifard

2

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18804512

Hiva Azizi

3

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18804512

Yasaman Taslimi

4

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18804512

Maribel Jiménez Alonso

5

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18804512

language of work or name

0 references

publication date

18 September 2008

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18804512

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18804512

26

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18804512

46

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18804512

5822-5829

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18804512

Advances in leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.065

7 January 2021

Leishmania/HIV co-infections: epidemiology in Europe.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.065

7 January 2021

The relationship between leishmaniasis and AIDS: the second 10 years

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.065

7 January 2021

Drug resistance in Indian visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.065

7 January 2021

Drug resistance in Leishmania: similarities and differences to other organisms

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.065

7 January 2021

Clinical and parasitological evaluation of dogs naturally infected by Leishmania (Leishmania) chagasi submitted to treatment with meglumine antimoniate

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.065

7 January 2021

Comparative efficacy of meglumine antimoniate and aminosidine sulphate, alone or in combination, in canine leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.065

7 January 2021

Balancing immunity and pathology in visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.065

7 January 2021

Immunologic markers of clinical evolution in children recently infected with Leishmania donovani chagasi

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.065

7 January 2021

Immunopathogenesis of infection with the visceralizing Leishmania species

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.065

7 January 2021

Leishmania and the leishmaniases: a parasite genetic update and advances in taxonomy, epidemiology and pathogenicity in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.065

7 January 2021

Leishmania vaccines: progress and problems.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.065

7 January 2021

Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.065

7 January 2021

Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.065

7 January 2021

Identification of a 30 kDa antigen from leishmania (L.) chagasi amastigotes implicated in protective cellular reponses in a murine model.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.065

7 January 2021

Immunization with the cysteine proteinase Ldccys1 gene from Leishmania (Leishmania) chagasi and the recombinant Ldccys1 protein elicits protective immune responses in a murine model of visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.065

7 January 2021

Cysteine proteases of parasitic organisms

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.065

7 January 2021

Leishmania Cysteine Proteinases: From Gene to Subunit Vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.065

7 January 2021

Cathepsin B-like cysteine proteinase-deficient mutants of Leishmania mexicana.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.065

7 January 2021

Functional analysis of cathepsin B-like cysteine proteases from Leishmania donovani complex. Evidence for the activation of latent transforming growth factor beta

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.065

7 January 2021

A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.065

7 January 2021

Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.065

7 January 2021

T helper (h)1/Th2 and Leishmania: paradox rather than paradigm

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.065

7 January 2021

Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generati

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.08.065

7 January 2021

Identifiers

10.1016/J.VACCINE.2008.08.065

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18804512

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/18804512

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46356731&oldid=2107582025"